YQ‐0629 can bind to the PAS‐B domain of HIF‐2α, inhibit the self‐renewal of BCSC, overcome BCSC chemoresistance, and inhibit tumor growth in vitro and in vivo, making it a promising candidate for targeted breast cancer therapy [84]. Here, EPAS1 is linked to neoplasm.